Structure-based Drug Design is an Essential Tool for Quicker and More Cost-Efficient Lead Discovery  

As an active player in the chemical industry, Alfa Chemistry decided to combine the power of computational chemistry with drug design and synthesis. This move aims to largely enhance the overall drug discovery efficiency and open up new possibilities for the pharmaceutical industry. Fairly recently, the company launched a series of structure-based drug design (SBDD) services, showing capabilities in virtual screening, flexible target sampling, skeleton transitions, de novo design, and more...